Lennox-Gastaut Syndrome (LGS) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Lennox-Gastaut Syndrome (LGS) Emerging Therapy and TPP Insights

Thelansis's "Lennox-Gastaut Syndrome (LGS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Lennox-Gastaut Syndrome (LGS) Overview

Lennox-Gastaut syndrome (LGS) is a severe, childhood-onset epilepsy syndrome marked by multiple seizure types and significant cognitive and behavioral impairment, arising from a wide range of underlying causes rather than a single genetic origin, which has long complicated efforts to build a unified treatment approach. Care today relies on adjunctive anti-seizure medications alongside surgical and device-based options such as nerve stimulation and corpus callosotomy, yet complete seizure freedom remains the exception, and the syndrome's broader toll on development and behavior is often inadequately addressed by therapies focused narrowly on seizure counts. The field is now moving beyond this symptom-first approach toward mechanism-based, individualized strategies, informed by a deepening understanding of the molecular pathways underlying different LGS etiologies, with an active pipeline of investigational compounds and early interest in genetically informed approaches for specific patient subgroups. For stakeholders, LGS represents a high-burden, complex condition where the next wave of value creation likely comes from precision-guided rather than broad-spectrum treatment.

Key Highlights

• In Germany, diagnosed Lennox-Gastaut Syndrome (LGS) cases are projected to increase from **6,787 in 2025 to 6,849 by 2035**.
• LGS is a rare, severe epileptic encephalopathy associated with multiple seizure types and cognitive impairment.
• Despite available antiseizure therapies, many patients continue to experience treatment-resistant seizures.
• Significant unmet need remains for therapies that provide sustained seizure control and improve quality of life.

Market Overview

• The Italy LGS market is projected to grow from **$50M in 2025 to $110M by 2035**.
• Market growth is driven by:
• Increasing adoption of novel antiseizure therapies
• Ongoing development of targeted treatment options
• Future growth will depend on therapies capable of achieving durable seizure reduction and improved patient outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Epygenix
• Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
• SK Life Science, Inc.
• NeuroPace
• Zogenix, Inc.
• Jazz Pharmaceuticals
• Longboard Pharmaceuticals